Compare Eli Lilly And Co (LLY) vs Upwork Inc (UPWK) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.

UPWK trades at $8.57, up 2.02% today, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing on revenue guidance, leading to a recent stock decline. Fundamentals show strong profitability with a 77.21% gross margin and 12.93% net income margin, while valuation ratios like P/E of 10.99 and P/S of 1.48 appear reasonable. Recent news highlights insider selling and ongoing securities fraud investigations.

The outlook for UPWK is cautious due to AI-driven competitive threats and weak guidance, though low valuation provides downside protection. Risks include declining active clients and legal scrutiny, but analyst consensus remains bullish with a $9.64 price target. Investment opportunity hinges on execution amid industry disruption.